Aim was the comparison of 3 different quadruple induction immunosuppressive Patients and Methods. In 4 groups compromising 8 patients each, treatment was either with ATG (F) (Gr.:I), anti CD25 Ab ( Basiliximab,Gr.:II), anti-LFA-1 (Gr.:III) on day 0 and 4 or a conventional triple drug (Gr.:IV) with CsA, MMF and MP. All groups were comparable concerning age, HLA-compatability and cold ischemic time. There were only a few side effects like fever, malaise and no tumor regimens in terms of graft-function, rejection and infectious episodes as well as side effects impairing safety and efficacy induction in the mean follow up time of 37 months (12-50). Creatinine after 3 and 12 months showed for I:127/131 mmol/l; II:146/150mmol/l; III:172/156mmol/l; IV:146-/150mmol/l. Rate of rejection was 0 in I, 3 in II, 1 in III und 5 in IV, only in I the rate of PRA was mean 22% against 0% in the other groups. Hospital stay was in I only 16 instead of 29, 28 und 31. CMV-Reactivation including treatment was 0,37%, 42% and 12%. The rate of urinary tract infections was 37%, 50%, 87% and 75% (first 3 months post Tx). Under quadruple therapy there was a decrease in values for function, rejection episodes and hospital stay. Infection episodes were only slightly elevated. The beneficial effects for polyclonal Ab´s might be seen in long-term effects as well as in vascular rejection episodes whereas monoclonal Ab´s plus is demonstrated through the near zero rate of side effects.